Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kunlun Bio is a synthetic biology company based in Beijing, China, that focuses on the sustainable production of high-value natural products through microbial fermentation. The company utilizes a proprietary platform integrating artificial intelligence and high-throughput screening to design and optimize metabolic pathways and enzymes. Its primary products include ergothioneine, rare ginsenosides, and other bioactive compounds used in the nutrition, cosmetics, and pharmaceutical industries. By replacing traditional extraction and chemical synthesis with bio-manufacturing, Kunlun Bio aims to provide more efficient and environmentally friendly solutions for the healthcare and wellness markets. The company is led by experienced founders from the synthetic biology industry and is backed by top-tier venture capital firms such as IDG Capital and Morningside Venture Capital.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kunlun Biotechnology.